polatuzumab vedotin + zanubrutinib + lenalidomide + rituximab

This is a four-drug combination regimen consisting of polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab. It is being investigated primarily for the treatment of diffuse large B-cell lymphoma (DLBCL), particularly in unfit or frail patients who may not tolerate standard regimens. - **Polatuzumab vedotin** is an antibody-drug conjugate targeting CD79b on B cells, delivering the cytotoxic agent monomethyl auristatin E to induce cell death. - **Zanubrutinib** is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), blocking B-cell receptor signaling and proliferation. - **Lenalidomide** is an immunomodulatory agent that affects multiple pathways including cytokine production and T-cell activation, with antiangiogenic and direct antitumor effects. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis via immune-mediated mechanisms. The combination aims to leverage complementary mechanisms—targeted cytotoxicity (polatuzumab vedotin), inhibition of key survival pathways (zanubrutinib), immune modulation (lenalidomide), and direct depletion of malignant B cells (rituximab)—to improve outcomes in DLBCL[2].

Brand names

None known as a fixed-dose combination product

Other names

Pola-ZR2 regimenPola-ZR-2 regimenPola-ZR 2 regimen